DRMA

0.50954.23%
KK

Kyri K. Van Hoose

Senior VP & CFO

Ms. Kyri K. Van Hoose, C.P.A, M.B.A., has been the Senior Vice President and the Chief Financial Officer at Dermata Therapeutics, Inc. since September 01, 2021. Ms. Van Hoose joined Turning Point Therapeutics, Inc. as Vice President, Accounting on May 5, 2021 and served as its Interim Principal Accounting Officer since May 14, 2021. Ms. Van Hoose previously served as chief financial officer of TEGA Therapeutics, Inc., a private biotechnology company, from September 2020 until May 2021. Prior to TEGA, Ms. Van Hoose served as Vice President, Finance for Curzion Pharmaceuticals, Inc., a private biopharmaceutical company, from November 2019 until its acquisition by Horizon Therapeutics plc in April 2020 and as Vice President, Finance of Avelas Biosciences, Inc., a clinical stage oncology company, from December 2017 to July 2019. From September 2005 to February 2016, Ms. Van Hoose held positions of increasing responsibilities at ACADIA Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, most recently as Senior Director of Finance and Corporate Controller. Ms. Van Hoose began her career at Deloitte and is a licensed Certified Public Accountant (California active). Ms. Van Hoose earned her BS in Accounting at the University of Southern California in May 2000 and earned her MBA in Finance Degree from the University of California, Irvine in June 2005.

Positions